HC Wainwright Issues Optimistic Forecast for Kamada Earnings

Kamada Ltd. (NASDAQ:KMDA) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Kamada in a research report issued on Thursday, January 8th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $0.44 for the year, up from their previous estimate of $0.41. HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.01). Kamada had a net margin of 11.70% and a return on equity of 7.89%. The firm had revenue of $47.01 million for the quarter, compared to analyst estimates of $154.21 million.

Several other research firms have also commented on KMDA. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a report on Wednesday, October 8th. Benchmark reissued a “buy” rating on shares of Kamada in a report on Thursday. Finally, Wall Street Zen raised Kamada from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.00.

Kamada Price Performance

KMDA stock opened at $8.04 on Monday. The firm has a market cap of $462.38 million, a price-to-earnings ratio of 22.33, a PEG ratio of 0.68 and a beta of 0.93. Kamada has a 1-year low of $5.54 and a 1-year high of $9.15. The firm has a fifty day moving average price of $7.04 and a two-hundred day moving average price of $7.13.

Institutional Investors Weigh In On Kamada

A number of hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new position in shares of Kamada during the first quarter worth approximately $206,000. NewEdge Advisors LLC raised its stake in Kamada by 119.9% during the 1st quarter. NewEdge Advisors LLC now owns 51,661 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 28,165 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Kamada during the 1st quarter worth $497,000. Jane Street Group LLC acquired a new position in Kamada during the 1st quarter worth $582,000. Finally, Huntleigh Advisors Inc. grew its stake in shares of Kamada by 3.9% in the second quarter. Huntleigh Advisors Inc. now owns 135,776 shares of the biotechnology company’s stock worth $1,052,000 after purchasing an additional 5,151 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.